Literature DB >> 1395046

Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients: evidence for reduced pineal activity and relevance of urinary determinations.

C Bartsch1, H Bartsch, A Schmidt, S Ilg, K H Bichler, S H Flüchter.   

Abstract

The circadian rhythms of melatonin and 6-sulfatoxymelatonin (aMT6s) were analyzed in serum and urine of young men (YM, n = 8), of elderly patients with benign prostatic hyperplasia (BPH, n = 7) and of patients of similar age with primary prostate cancer (PC, n = 9). The data expressed as concentration and in urine also as hourly excreted quantity were analyzed chronobiologically by the single cosinor method and, subsequently submitted to linear regression analyses. Circadian rhythms were detected in all cases except for the excreted quantity of melatonin. The circadian patterns of melatonin and aMT6s in serum were very similar in the different groups and regression analyses showed close correlations between both variables. MESOR and amplitude were significantly depressed in PC (40-60%) as compared to BPH and YM indicating that the depression of serum melatonin in PC is due to a reduced pineal activity and is not caused by an enhanced metabolic degradation in the liver. Acrophases of serum melatonin occurred between 01:34 and 03:26 h and of serum aMT6s between 03:58 and 04:35 h. Circadian rhythms similar to those of serum melatonin and aMT6s were found in urine, particularly for aMT6s excretion as well as melatonin concentration; the determination of both parameters in overnight urine samples closely correlated with the nocturnal peak of circulating melatonin. These results imply that it is feasible to estimate changes in pineal function of prostate cancer patients by means of non-invasive determination using urinary melatonin and aMT6s.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1395046     DOI: 10.1016/0009-8981(92)90164-l

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  23 in total

1.  Does "clock" matter in prostate cancer?

Authors:  Yong Zhu; Tongzhang Zheng; Richard G Stevens; Yawei Zhang; Peter Boyle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-01       Impact factor: 4.254

Review 2.  Circadian disruption, sleep loss, and prostate cancer risk: a systematic review of epidemiologic studies.

Authors:  Lara G Sigurdardottir; Unnur A Valdimarsdottir; Katja Fall; Jennifer R Rider; Steven W Lockley; Eva Schernhammer; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-05-07       Impact factor: 4.254

3.  Deregulated expression of circadian clock and clock-controlled cell cycle genes in chronic lymphocytic leukemia.

Authors:  Sobia Rana; Mustafa Munawar; Adeela Shahid; Meera Malik; Hafeez Ullah; Warda Fatima; Shahida Mohsin; Saqib Mahmood
Journal:  Mol Biol Rep       Date:  2013-11-05       Impact factor: 2.316

4.  Sleep disruption among older men and risk of prostate cancer.

Authors:  Lara G Sigurdardottir; Unnur A Valdimarsdottir; Lorelei A Mucci; Katja Fall; Jennifer R Rider; Eva Schernhammer; Charles A Czeisler; Lenore Launer; Tamara Harris; Meir J Stampfer; Vilmundur Gudnason; Steven W Lockley
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-05       Impact factor: 4.254

5.  Impact of Comorbidities on Prostate Cancer Stage at Diagnosis in Florida.

Authors:  Hong Xiao; Fei Tan; Pierre Goovaerts; Georges Adunlin; Askal Ayalew Ali; Clement K Gwede; Youjie Huang
Journal:  Am J Mens Health       Date:  2014-12-26

6.  Altered time structure of neuro-endocrine-immune system function in lung cancer patients.

Authors:  Gianluigi Mazzoccoli; Gianluigi Vendemiale; Angelo De Cata; Stefano Carughi; Roberto Tarquini
Journal:  BMC Cancer       Date:  2010-06-21       Impact factor: 4.430

7.  GEOGRAPHICALLY-WEIGHTED REGRESSION ANALYSIS OF PERCENTAGE OF LATE-STAGE PROSTATE CANCER DIAGNOSIS IN FLORIDA.

Authors:  Pierre Goovaerts; Hong Xiao; Georges Adunlin; Askal Ali; Fei Tan; Clement K Gwede; Youjie Huang
Journal:  Appl Geogr       Date:  2015-08-01

8.  Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men.

Authors:  Lara G Sigurdardottir; Sarah C Markt; Jennifer R Rider; Sebastien Haneuse; Katja Fall; Eva S Schernhammer; Rulla M Tamimi; Erin Flynn-Evans; Julie L Batista; Lenore Launer; Tamara Harris; Thor Aspelund; Meir J Stampfer; Vilmundur Gudnason; Charles A Czeisler; Steven W Lockley; Unnur A Valdimarsdottir; Lorelei A Mucci
Journal:  Eur Urol       Date:  2014-08-05       Impact factor: 20.096

Review 9.  Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities.

Authors:  Wamidh H Talib; Ahmad Riyad Alsayed; Alaa Abuawad; Safa Daoud; Asma Ismail Mahmod
Journal:  Molecules       Date:  2021-04-25       Impact factor: 4.411

Review 10.  Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks.

Authors:  Mariangela Rondanelli; Milena Anna Faliva; Simone Perna; Neldo Antoniello
Journal:  Aging Clin Exp Res       Date:  2013-09-18       Impact factor: 3.636

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.